All In Biotech

Drug Trial Radar · NCT05151731

A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edema

A Phase II, Multicenter, Randomized, Double Masked, Active Comparator-Controlled Study to Investigate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7200220 Administered Intravitreally in Patients With Diabetic Macular Edema

Last checked: Nov 20, 2026Latest source record: May 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 394 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

394

Actual

Start

Dec 31, 2021

Primary completion

Nov 6, 2024

Study completion Apr 21, 2025

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Dec 9, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study BP43445 is a phase II, multicenter, randomized, double-masked, active comparator-controlled study to investigate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of vamikibart administered intravitreally in participants with diabetic macular edema. Only one eye will be chosen as the study eye. The duration of the study will be up to 76 weeks.

Conditions

  • Diabetic Macular Edema

Interventions

  • VamikibartDrug

    Vamikibart will be administered by IVT injection as specified in each treatment arm.

  • RanibizumabDrug

    Ranibizumab 0.5 mg will be administered to the participants by IVT injection, as specified in the treatment arm.

  • Sham ProcedureOther

    Sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. Sham procedure will be administered to participants in the Q8W arms at applicable visits to maintain masking between treatment arms.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Best-Corrected Visual Acuity (BCVA) Averaged Over Week 44 and Week 48, in Treatment-naïve ParticipantsTime frame: Baseline, Weeks 44 and 48

Locations

74 sites in 9 countries. Site status is shown where the registry gives one.

  • Win Retina

    Arcadia, California

  • Retina Consultants, San Diego

    Poway, California

  • Retinal Consultants Med Group

    Sacramento, California

  • Bay Area Retina Associates

    Walnut Creek, California

  • Colorado Retina Associates, PC

    Lakewood, Colorado

  • Emerson Clinical Research Institute LLC

    Washington D.C., District of Columbia

  • Rand Eye

    Deerfield Beach, Florida

  • National Ophthalmic Research Institute

    Fort Myers, Florida

  • Florida Retina Institute

    Orlando, Florida

  • Retina Vitreous Associates of Florida

    St. Petersburg, Florida

  • Retina Specialists of Tampa

    Wesley Chapel, Florida

  • Butchertown Clinical Trials

    Louisville, Kentucky

  • Cumberland Valley Retina PC

    Hagerstown, Maryland

  • Deep Blue Retina PLLC

    Southaven, Mississippi

  • Sierra Eye Associates

    Reno, Nevada

  • Opthalmic Consultants of LI

    Lynbrook, New York

  • University of Rochester Flaum Eye Institute

    Rochester, New York

  • Western Carolina Retinal Associate PA

    Asheville, North Carolina

  • Wake Forest Baptist Medical Center

    Winston-Salem, North Carolina

  • Meridian Clinical Research

    Cincinnati, Ohio

  • Verum Research LLC

    Eugene, Oregon

  • EyeHealth Northwest

    Portland, Oregon

  • Erie Retinal Surgery

    Erie, Pennsylvania

  • Eye Care Specialists, PC

    Kingston, Pennsylvania

  • Sewickley Eye Group

    Sewickley, Pennsylvania

  • Charleston Neuroscience Institute

    Ladson, South Carolina

  • Black Hills Eye Institute

    Rapid City, South Dakota

  • Retina Consultants of Nashville

    Nashville, Tennessee

  • Texas Retina Associates

    Arlington, Texas

  • Austin Clinical Research LLC

    Austin, Texas

  • Retina Consultants of Texas

    Bellaire, Texas

  • Valley Retina Institute P.A.

    McAllen, Texas

  • Retina Consultants of Texas

    The Woodlands, Texas

  • Strategic Clinical Research Group, LLC

    Willow Park, Texas

  • Piedmont Eye Center

    Lynchburg, Virginia

  • Wagner Macula & Retina Center

    Norfolk, Virginia

  • Organizacion Medica de Investigacion

    Buenos Aires, Argentina

  • Centro Oftalmologico Dr. Charles S.A.

    Capital Federal, Argentina

  • Oftalmos

    Capital Federal, Argentina

  • Buenos Aires Mácula

    Ciudad Autonoma Buenos Aires, Argentina

Showing 40 of 74 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.